A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Malignant Melanoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A Randomized Controlled Phase II Multicenter Clinical TrialMasking: Triple (Participant, Care Provider, Investigator)Masking Description: Persons that are masked/ blinded for which medication the patient receives: participant, treating physician/ team (including the person giving the intradermal injection) and peron who collects the data.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04126876
- Collaborators
- Idera Pharmaceuticals, Inc.
- Investigators
- Principal Investigator: Tanja de Gruijl VU University Medical Center Principal Investigator: Alfons JM van den Eertwegh VU University Medical Center
Get Well Soon